Madrid

• A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer Recruiting
  2025-524168-39-00 1 2026-04-13 ​​Platinum-Resistant ovarian cancer​
• Dose-finding study of LAD603 in adults with alopecia areata Recruiting
  2025-523342-27-00 4 2026-04-10 Alopecia areata
• C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer. Recruiting
  2025-521756-39-00 1 2026-04-09 Non-muscle invasive bladder cancer (NMIBC)
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Recruiting
  2025-523686-15-00 1 2026-04-08 Advanced or Metastatic Solid Tumors
• A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Recruiting
  2025-521792-31-01 5 2026-04-07 Homozygous Familial Hypercholesterolemia (HoFH)
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting
  2025-520902-37-00 4 2026-04-01 Non-small cell lung cancer stage IV
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V … Recruiting
  2025-521966-91-00 4 2026-03-31 Refractory Metastatic Breast Cancer with Liver Dominant Disease
• Study to evaluate the effectiveness, safety, and quality of life of Bilaxten, an allergy medication, in children Recruiting
  2024-519550-36-00 6 2026-03-30 Allergic rhinoconjunctivitis
• VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting
  2024-512436-29-00 11 2026-03-27 CARDIOVASCULAR DISEASES
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• A Phase 1 Study of IM-1021 in Participants with Advanced Cancer Recruiting
  2025-523160-20-00 1 2026-03-23 Advanced solid tumors
• A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro … Recruiting
  2025-522892-27-00 4 2026-03-21 Bronchiectasis
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• A clinical study of MK-3120 in people with bladder cancer (MK-3120-003) Recruiting
  2025-520467-40-00 9 2026-03-16 High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a … Recruiting
  2025-520675-86-00 4 2026-03-10 Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li

Showing 313–336 of 3,550 trials